Literature DB >> 32681366

The effect of calcium and vitamin D compounds on bone mineral density in patients undergoing glucocorticoid therapies: a network meta-analysis.

Jiawen Deng1, Zachary Silver2, Emma Huang3, Elena Zheng4, Kyra Kavanagh2, Jannusha Panicker5.   

Abstract

INTRODUCTION/
OBJECTIVES: The objective of our systematic review and network meta-analysis (NMA) is to investigate which vitamin D and/or calcium regimen would yield the greatest increase in lumbar spine, femoral neck, and total hip bone mineral density (BMD) in adult patients undergoing glucocorticoid therapy.
METHOD: We performed NMAs based on a prospectively developed protocol. A database search of MEDLINE, EMBASE, Web of Science, CINAHL, CENTRAL and Chinese databases were conducted for relevant randomized controlled trials (RCTs). Outcomes were percentage change in lumbar spine, femoral neck, and total hip BMD from baseline.
RESULTS: We included 16 RCTs containing 1073 eligible patients in our analysis. We found alfacalcidol+calcium to yield the greatest percentage increase in lumbar spine BMD (MD 6.05, 95% credible interval [CrI] - 4.18 to 16.18) compared to no treatment, and calcitriol+calcium to yield the greatest percentage increase in femoral neck BMD (MD 8.46, 95% CrI - 4.74 to 21.51) compared to no treatment. Cholecalciferol+calcium ranked first in terms of its ability to increase total hip BMD; however this finding needs to be interpreted with caution due to low sample sizes in the cholecalciferol+calcium treatment arm. None of the treatment arms ruled out the possibility of no effect for any outcome.
CONCLUSIONS: Alfacalcidol and calcitriol were the most efficacious treatment arms for increasing lumbar spine and femoral neck BMD, respectively. Our findings need to be validated by further investigations using larger, better-designed RCTs. Key Points •The efficacy of calcium/vitamin D compounds was examined using network meta-analyses. •Alfacalcidol + calcium yielded the greatest increase in lumbar spine BMD, calcitriol + calcium yielded the greatest increase in femoral neck BMD. •Future guidelines should place greater emphasis on the efficacy of different vitamin D compounds.

Entities:  

Keywords:  Bone mineral density; Calcium; Glucocorticoid; Network meta-analysis; Osteoporosis; Vitamin D

Mesh:

Substances:

Year:  2020        PMID: 32681366     DOI: 10.1007/s10067-020-05294-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Network meta-analysis: the highest level of medical evidence?

Authors:  Erlend G Faltinsen; Ole Jakob Storebø; Janus C Jakobsen; Kim Boesen; Theis Lange; Christian Gluud
Journal:  BMJ Evid Based Med       Date:  2018-03-14

2.  Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man.

Authors:  T J Hahn; L R Halstead; D T Baran
Journal:  J Clin Endocrinol Metab       Date:  1981-01       Impact factor: 5.958

Review 3.  2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Authors:  Lenore Buckley; Gordon Guyatt; Howard A Fink; Michael Cannon; Jennifer Grossman; Karen E Hansen; Mary Beth Humphrey; Nancy E Lane; Marina Magrey; Marc Miller; Lake Morrison; Madhumathi Rao; Angela Byun Robinson; Sumona Saha; Susan Wolver; Raveendhara R Bannuru; Elizaveta Vaysbrot; Mikala Osani; Marat Turgunbaev; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2017-06-06       Impact factor: 10.995

4.  Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6.

Authors:  Sylvie Huybers; Ton H J Naber; René J M Bindels; Joost G J Hoenderop
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-08-10       Impact factor: 4.052

Review 5.  Systemic lupus erythematosus: an update.

Authors:  Vera Golder; Alberta Hoi
Journal:  Med J Aust       Date:  2017-03-20       Impact factor: 7.738

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

7.  Dose-related patterns of glucocorticoid-induced side effects.

Authors:  D Huscher; K Thiele; E Gromnica-Ihle; G Hein; W Demary; R Dreher; A Zink; F Buttgereit
Journal:  Ann Rheum Dis       Date:  2008-08-06       Impact factor: 19.103

Review 8.  Glucocorticoid-induced osteoporosis: pathophysiology and therapy.

Authors:  E Canalis; G Mazziotti; A Giustina; J P Bilezikian
Journal:  Osteoporos Int       Date:  2007-06-14       Impact factor: 4.507

9.  The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.

Authors:  Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2015-06-02       Impact factor: 25.391

10.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
View more
  1 in total

Review 1.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.